Ascension Sciences Unveils Licensed Research and Development Laboratory

VANCOUVER, October 22, 2020 — Ascension Sciences Inc. (“ASI” of the “Company”), an independent laboratory focused on nanoparticle development for cannabinoid products and therapeutics, is pleased to announce the completion of a licensed R&D laboratory. With the headquarters based in Vancouver, Canada, the facility will support the research and development pipeline for the Company’s growing Contract Research (CRO) operations. 

The establishment of ASI’s laboratory is essential for meeting the demands of firms looking to extend their research capabilities. From calculating nanoparticle PDI to API characterization using liquid chromatography (HPLC) , the Company’s formulation technology and testing services include nanoparticle development, shelf-life stability testing, encapsulation efficiency, and dissolution profiles. 

“The completion of this R&D laboratory expands ASI’s capacity for formulation development on cannabinoids for novel therapies. Using efficient screening techniques, we are eager to offer our CRO services and expertise in nanotechnology across North America and internationally,” said Tomas Skrinskas, Founder & CEO of Ascension Sciences. 

For media inquiries, please contact [email protected]. Stay connected with ASI on LinkedIn and Twitter for the latest news.

SOURCE Ascension Sciences Inc.

About Ascension Sciences

Employing nanoparticle formulation technology from the cutting edge of genetic medicine, Ascension Sciences Inc. (ASI) is developing cannabinoid nano delivery platforms and techniques for the pharma and nutraceutical industries. ASI’s R&D and formulation development services are an efficient option for research driven firms that require the advantages of nanoparticle delivery for their active ingredients.

 For more information, please visit